A phase I dose escalation clinical trial to evaluate the safety and immunogenicity of the EP HIV-1090 DNA vaccine in healthy, HIV-1 uninfected adult participants.

Trial Profile

A phase I dose escalation clinical trial to evaluate the safety and immunogenicity of the EP HIV-1090 DNA vaccine in healthy, HIV-1 uninfected adult participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2012

At a glance

  • Drugs EP 1090 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 03 May 2012 Actual end date (1 Sep 2005) added as reported by ClinicalTrials.gov.
    • 05 Oct 2007 Status changed from in progress to completed.
    • 17 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top